The fifth set of listing standards for the Science and Technology Innovation Board has been restarted, and He Yuan Biological's IPO application will be reviewed on July 1st.

Last night, the Shanghai Stock Exchange Listing Committee issued a notice for the review meeting, scheduled to be held on July 1st to review the listing application of Wuhan Heyuan Bio-Tech Co., Ltd., a potential listed company on the Sci-Tech Innovation Board. According to Heyuan Bio's draft prospectus, the company plans to list under the fifth set of standards on the Sci-Tech Innovation Board. This is the first company to present under the fifth set of standards on the Sci-Tech Innovation Board since China Securities Regulatory Commission Chairman Wu Qing announced the establishment of the Sci-Tech Growth Board and the resumption of listing for unprofitable companies under the fifth set of standards on the Sci-Tech Innovation Board on June 18th at the Lujiazui Forum 2025. The draft prospectus shows that Heyuan Bio is a biopharmaceutical company mainly engaged in innovative drug research and development, with its core product HY1001 having completed Phase III clinical trials and being included in the priority review program by the National Medical Products Administration. It is expected to become the first domestically listed recombinant human serum albumin drug. There are currently 20 companies listed under the fifth set of standards on the Sci-Tech Innovation Board, with 19 being innovative drug R&D companies and 1 being a high-end medical device R&D company. As of June this year, out of the 20 companies listed under the fifth set of standards, 19 have successfully listed their core products, while the remaining company has already submitted an application for the listing of its core product.